For young breast cancer patients with clinical stages of ⅡA~ⅢC, there was no statistical difference in pCR rate and ORR whether or not using goserelin during NAC. However, it is still necessary to expand the sample size and carry out a longer follow-up to evaluate the effect of goserelin on the long-term survival of young patients.

P2, N=104, Recruiting, Fudan University | Trial completion date: Mar 2025 --> Sep 2027 | Trial primary completion date: Mar 2025 --> Mar 2027

P3, N=280, Active, not recruiting, University Medical Center Groningen | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Oct 2027

P=N/A, N=5793, Recruiting, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University

P4, N=0, Recruiting, children's hospital of fudan university; children's hospital of fudan university

P4, N=200, Recruiting, The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University

P=N/A, N=10, Not yet recruiting, Alfred Health

The results of the tests showed that Triptorelin-AuNPs nanoparticles have the ability to cause targeted sensitivity in MCF-7 cells with triptorelin peptide receptors.

P3, N=2672, Completed, ETOP IBCSG Partners Foundation | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Oct 2024

P2, N=180, Recruiting, Weill Medical College of Cornell University | Trial primary completion date: Dec 2025 --> May 2026

P=N/A, N=100, Recruiting, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Trial completion date: May 2025 --> May 2026

P1, N=150, Not yet recruiting, Shaare Zedek Medical Center

Given the tumor's limited sensitivity to chemotherapy, she was treated with neoadjuvant endocrine therapy (ET) using fulvestrant, palbociclib, and leuprolide. This case supports the potential role of endocrine-based targeted therapy in managing pediatric LGSOC, offering a viable alternative for patients with limited treatment options. Further research is needed to optimize treatment strategies and improve survival outcomes in this rare population.

This real-world analysis indicates that 3-month goserelin 10.8 mg is non-inferior to monthly 3.6 mg among premenopausal women with breast cancer in terms of 12-month rwEFS rate. These findings may support the use of the 3-month goserelin 10.8 mg as an alternative treatment option to monthly goserelin 3.6 mg for this patient population.

P=N/A, N=1266, Completed, The First Affiliated Hospital of Zhengzhou University | Unknown status --> Completed | N=50 --> 1266 | Trial completion date: Aug 2018 --> Dec 2024

At nine years and eight months, triptorelin treatment was initiated, leading to a reduction of pubic hair, stabilization of testicular volume, and a stature of -1.64 SD at the age of 13 years. Despite known factors influencing puberty, the precise physiological mechanisms behind its initiation remain unclear. This case provides valuable insights for understanding the genotype-phenotype relationship in Costello syndrome.

P2, N=90, Active, not recruiting, Rutgers, The State University of New Jersey | Trial completion date: Jan 2024 --> Nov 2026 | Trial primary completion date: Jan 2024 --> Nov 2025 | Recruiting --> Active, not recruiting

Overall, our results reveal that GnRHR suppresses the malignant progression of TNBC by upregulating FOS and IFI44L. Goserelin slows down the proliferation of TNBC tumors in vivo through the GnRHR/FOS/IFI44L pathway, which may present a new therapeutic approach for the management of TNBC.

The findings of this systematic review highlight the benefits of adding goserelin to endocrine therapies for OFS and chemotherapy for OFP in early-stage breast cancer. Additionally, scientific data supporting OFS (including goserelin) in combination with newer agents such as cyclin-dependent kinase 4 and 6 inhibitors and bone-modifying agents are emerging.

P3, N=6, Terminated, Eurofarma Laboratorios S.A. | N=68 --> 6 | Recruiting --> Terminated; Low recruitment rate and number of subjects is less than required after 3 years.

Of 26 patients who received goserelin at an AIS, all patients reported the absence of menses with no tolerability concerns. For patients who may want to avoid abdominal administration, injection of goserelin at an AIS appears to be a viable strategy and offers flexibility for OFS management in breast cancer.

P2, N=28, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2025 --> Jan 2026

P3, N=93, Recruiting, Foresee Pharmaceuticals Co., Ltd. | Trial completion date: Dec 2025 --> Jun 2026

P3, N=60, Recruiting, Children's Oncology Group | Not yet recruiting --> Recruiting

P3, N=148, Not yet recruiting, Foresee Pharmaceuticals Co., Ltd.

P3, N=600, Active, not recruiting, Abdenour Nabid | Trial completion date: Dec 2023 --> Dec 2027 | Trial primary completion date: Dec 2023 --> Dec 2026

P3, N=148, Not yet recruiting, Foresee Pharmaceuticals Co., Ltd.

Triptorelin is preferred among luteinizing hormone-releasing hormone analogs, though all options have similar efficacies. The outcomes of this consensus offer valuable clinical guidance, enabling individualized and evidence-based approaches for OFS in Indian patients with HR+ HER2- eBC.

P=N/A, N=110, The First Affiliated Hospital of Sun Yat-sen University; The First Affiliated Hospital of Sun Yat-sen University

P=N/A, N=96, Shanghai Children's Hospital; Shanghai Children's Hospital

P=N/A, N=60, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province People's Hospital); The First Affiliated Hospital of Nanjing Medical Uni

P4, N=88, Guangdong Provincial People's Hospital; Guangdong Provincial People's Hospital

P2, N=30, Recruiting, German Oncology Center, Cyprus

P=N/A, N=18, Completed, University of Chicago | Active, not recruiting --> Completed | N=80 --> 18

P=N/A, N=450, Active, not recruiting, Ipsen | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2026

P=N/A, N=10, Not yet recruiting, ART Fertility Clinics LLC

P=N/A, N=349, Active, not recruiting, Peking University People's Hospital | Recruiting --> Active, not recruiting | N=240 --> 349

P=N/A, N=0, Withdrawn, Sir Mortimer B. Davis - Jewish General Hospital | N=65 --> 0 | Not yet recruiting --> Withdrawn

P3, N=784, Recruiting, The University of Hong Kong | Trial completion date: Dec 2024 --> Mar 2025

P2/3, N=102, Active, not recruiting, Sir Mortimer B. Davis - Jewish General Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2025 --> Apr 2027

P3, N=53, Recruiting, Debiopharm International SA | Trial completion date: Dec 2027 --> Mar 2028 | Trial primary completion date: Jul 2026 --> Dec 2026

The findings of the current study demonstrated that the simultaneous consumption of a certain amount of broccoli extract and SI can be considered as a promising therapeutic strategy for treatment of endometriosis.